Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon Sep 06, 2021 2:31pm
307 Views
Post# 33816870

RE:Non optimized vs optimized

RE:Non optimized vs optimized

To be more thorough, to date 27 patients have been treated at a therapeutic dose ( high dose of drug).  Of those 13 have had a non-optimized treatment procedure  (patient #4 from PH1 and 1st 12 treated patients from PH2.  The remaining 14 patients in total have received an Optimized Treatment  Procedure ( patients # 5 & 6 fro PH1 and patients #13-24 from PH2).

 Non-optimized  Treatment Arm of 13 ( undertreated by 39-85%):  at 90 days post treatment 3 are CR and 2 are PR partial response and remaining   8  NR or no response ( unchanged CIS), but no progression . 23% CR

Optimized Treatment Arm of 14 patients:  6 pending data ( recently treated not yet 90 days), thus 8 with data showing 6 CR or complete response and 1 PR and 1 NR.  ( NR patient sadly died of unrelated issue and was counted as a non responder even though his urine cytology test was negative showing no presence of cancer at 30 days with a negative predictive value of about 95% IMO it is very likely that patient was CR, but cannot be counted as such).  So 75% CR at a minimum so far.  Hoping pending 6 patients will fare as well to confirm strong efficacy.  

Also great to see that both Optimized treated patients fro PH1 were still CR at 2 years mark after 1 single treatment instillation.  All IMO GLTA.


enriquesuave wrote:

1st 12 patients undertreated by 39-85% yielded a 25% CR  or 3 patients at 90 days 
6 optimized treated patients yielded 67% or 4 out of 6 patients and maybe would have been 5 as one patient died after negative urinate cytology.  

 Hence Optimized is about 2-4 Times as likely to get CR at 90 days.  IMO 



<< Previous
Bullboard Posts
Next >>